Format

Send to

Choose Destination
Future Med Chem. 2018 Jun 1;10(12):1395-1398. doi: 10.4155/fmc-2018-0090. Epub 2018 May 23.

Advocating for mutually beneficial access to shelved compounds.

Author information

1
Vanderbilt Institute for Clinical & Translational Research, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600, Nashville, TN 37203, USA.
2
Center for Knowledge Management, Vanderbilt University Medical Center, 3401 West End Avenue, Suite 304, Nashville, TN 37203, USA.
3
Department of Pediatrics, Division of Infectious Diseases, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN 37232, USA.
4
Department of Medicine, Division of Allergy, Pulmonary, & Critical Care Medicine, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN 37232, USA.
5
Center for Technology Transfer & Commercialization, Vanderbilt University, 1207 17th Avenue South, Suite 105, Nashville, TN 37212, USA.

KEYWORDS:

drug industry; drug repurposing; government regulation; nelivaptan; shelved compounds; tax incentives 

PMID:
29788759
DOI:
10.4155/fmc-2018-0090
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center